Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer

Molecular Therapy

Volumn 10, Issue 6, 2004, Pages 1059-1070

  Kaliberov, Sergey A ^a   Kaliberova, Lyudmila N ^a   Stockard, Cecil R ^b   Grizzle, William E ^b   Buchsbaum, Donald J ^a  

^a The University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Adenoviral vector; Antiangiogenesis gene therapy; FLT 1; Prostate cancer; Radiation; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INVASION; CANCER RADIOTHERAPY; CELL DEATH; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; GENE THERAPY; GENE TRANSFER; GROWTH INHIBITION; HUMAN; HUMAN CELL; IONIZING RADIATION; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION; GENE THERAPY; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; PROTEINS; RADIATION, IONIZING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 10344225606     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.08.024     Document Type: Article

References (53)

1. A. Jemal et al. Cancer statistics CA J. Cancer Clin. 52 2002 23-47
2. P.F. Schellhammer D.F. Lynch Are monotherapy options reasonable for T3 prostate cancer? Semin. Urol. Oncol. 15 1997 207-214
3. W.B. Isaacs Molecular genetics of prostate cancer Cancer Surv. 25 1995 357-379
4. M.S. Steiner J.R. Gingrich R.D. Chauhan Prostate cancer gene therapy Surg. Oncol. Clin. North Am. 11 2002 607-620
5. J. Folkman Angiogenesis and apoptosis Semin. Cancer Biol. 13 2003 159-167
6. D. Feng et al. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors J. Histochem. Cytochem. 48 2000 545-556
7. H.F. Dvorak et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels J. Exp. Med. 174 1991 1275-1278
8. F.A. Ferrer et al. Expression of vascular endothelial growth factor receptors in human prostate cancer Urology 54 1999 567-572
9. M. Fakhari et al. Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma J. Pediatr. Surg. 37 2002 582-587
10. S. Soker et al. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype Am. J. Pathol. 159 2001 651-659
11. C.N. Sternberg What's new in the treatment of advanced prostate cancer? Eur. J. Cancer 39 2003 136-146
12. F.A. Scappaticci et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice Mol. Ther. 3 2001 186-196
13. St J.A. George Gene therapy progress and prospects: Adenoviral vectors Gene Ther. 10 2003 1135-1141
14. S.A. Nicklin et al. Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors Cancer Lett. 201 2003 165-173
15. S.R. Wiley et al. Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673-682
16. G. Pan et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL Science 277 1997 815-818
17. P. Schneider et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB Immunity 7 1997 831-836
18. N.J. Mabjeesh H. Zhong J.W. Simons Gene therapy of prostate cancer: current and future directions Endocr. Relat. Cancer 9 2002 115-139
19. S.J. Collis K. Khater T.L. DeWeese Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy J. World Urol. 21 2003 275-289
20. S.A. Nicklin et al. Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium Hypertension 38 2001 65-70
21. P.N. Reynolds et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo Nat. Biotechnol. 19 2001 838-842
22. A. Abdollahi et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro Cancer Res. 63 2003 3755-3763
23. N. Weidner et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am. J. Pathol. 143 1993 401-409
24. M.C. Bettencourt et al. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy J. Urol. 160 1998 459-465
25. M.D. Balbay et al. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor Clin. Cancer Res. 5 1999 783-789
26. J.L. Duque et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer Urology 54 1999 523-527
27. Z. von Marschall et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop Gastroenterology 119 2000 1358-1372
28. M.W. Jackson et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer Cancer Res. 62 2002 854-859
29. S.R. Denmeade X.S. Lin J.T. Isaacs Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer Prostate 28 1996 251-265
30. H. Walczak et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat. Med. 5 1999 157-163
31. A. Ashkenazi et al. Safety and antitumor activity of recombinant soluble Apo2 ligand J. Clin. Invest. 104 1999 155-162
32. D. Lawrence et al. Differential hepatocyte toxicity of recombinant Apo2L-TRAIL versions Nat. Med. 7 2001 383-385
33. H.N. LeBlanc A. Ashkenazi Apo2L-TRAIL and its death and decoy receptors Cell Death Differ. 10 2003 66-75
34. T.S. Griffith et al. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis J. Immunol. 165 2000 2886-2894
35. T.S. Griffith E.L. Broghammer Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus Mol. Ther. 4 2001 257-266
36. J. Lee M. Hampl P. Albert H.A. Fine Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector Neoplasia 4 2002 312-323
37. X. Huang et al. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft Gene Ther. 9 2002 1379-1386
38. T. Lin et al. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effect on primary human hepatocytes Cancer Res. 62 2002 3620-3625
39. T. Lin et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells Oncogene 21 2002 8020-8028
40. S. Armeanu et al. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes Cancer Res. 63 2003 2369-2372
41. C.C. Parker D.P. Dearnaley Radical radiotherapy for prostate cancer Cancer Treat. Rev. 29 2003 161-169
42. B.S. Teh et al. Combining radiotherapy with gene therapy (from the bench to the bedside): A novel treatment strategy for prostate cancer Oncologist 7 2002 458-466
43. G. Atkinson S.J. Hall Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer Urology 54 1999 1098-1104
44. C.W. Stevens M. Zeng G.J. Cerniglia Ionizing radiation greatly improves gene transfer efficiency in mammalian cells Hum. Gene Ther. 7 1996 1727-1734
45. C. Belka et al. Apoptosis-modulating agents in combination with radiotherapy - current status and outlook Int. J. Radiat. Oncol. Biol. Phys. 58 2004 542-554
46. D.J. Waxman P.S. Schwartz Harnessing apoptosis for improved anticancer gene therapy Cancer Res. 63 2003 8563-8572
47. B. Gliniak T. Le Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11 Cancer Res. 59 1999 6153-6158
48. A.M. Chinnaiyan et al. A combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy Proc. Natl. Acad. Sci. USA 97 2000 1754-1759
49. B. Nicholson D. Theodorescu Angiogenesis and prostate cancer tumor growth J. Cell. Biochem. 91 2004 125-150
50. M. Garcia-Barros et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis Science 300 2003 1155-1159
51. S.A. Kaliberov et al. Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells Mol. Ther. 6 2002 190-198
52. V. Dressler G. Muller J. Suhnel CombiTool - a new computer program for analyzing combination experiments with biologically active agents Comput. Biomed. Res. 32 1999 145-160
53. T.C. Chou P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzymol. Regul. 22 1984 27-55